Abstract
This study included 20 selected female patients with breast cancer, 30 of their female relatives (sisters and daughters), and 10 healthy females as a control group. Genomic DNA was extracted from peripheral blood lymphocytes of all the subjects, and the polymerase chain reaction was carried out using specific primers for BRCA1 (exons 2 and 8) and BRCA2 (exons 9, 11, and 21). The mutations were detected using a single-strand conformation polymorphism assay and heteroduplex analysis. Finally, the sample variants and their controls were sequenced. Mutations were detected in 44% of the study population, with 18% found in the BRCA1 gene and 26% attributed to BRCA2. Five sequence variants were identified, including two frameshift mutations, one nonsense mutation, and two missense mutations. Therefore, we conclude that germline mutations in two major genes, BRCA1 and BRCA2, may have an important influence on the predisposition and development of familial breast cancer.
Similar content being viewed by others
References
American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406
Barkardottir RB, Sarantaus L, Arason A, Vehmanen P, Bendahl PO, Kainu T, Syrjäkoski K, Krahe R, Huusko P, Pyrhönen S, Holli K, Kallioniemi OP, Egilsson V, Kere J, Nevanlinna H (2001) Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet 9:773–779
Bicka L, Kuzmak J, Rola M, Beier D (2002) Detection of genetic diversity among bovine leukemia virus population by single-strand conformational polymorphism analysis. Bull Vet Inst Pulawy 46:205–212
Boakye DA, Tang J, Truc P, Merriweather A, Unnasch TR (1999) Identification of blood meals in haematophagous Diptera by cytochrome B heteroduplex analysis. Med Vet Entomol 13:282–287
Calzone KA, Stopfer J, Blackwood A (1997) Establishing a cancer risk evaluation program. Cancer Pract 5:228–233
Claus EB (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324
Couch JF, DeShano ML, Blackwood MA (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409–1415
Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34:1416–1427
Eachkoti R, Hussain I, Afroze D, AejazAziz S, Jan M, Shah ZA, Das BC, Siddiqi MA (2007) BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Lett 248:308–320
Easton DF, Bishop DT, Ford D (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52:678–701
Easton DF, Ford D, Bishop DT (1995) The Breast Cancer Linkage Consortium: breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–571
El Gezeery A, Mahmud N, Moustafa A, Mahrous H, Mahmoud H, Abd El-Menam N (2008) BRCA1 gene mutation in familial breast cancer. Turkish J Cancer 38:167–174
Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base 5, version 2.0. IARC Press, Lyon
Goldgar DE, Easton DF, Deffenbaugh AM (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535–544
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689
Ibrahim SS, Hafez EE, Hashishe MM (2010) Presymptomic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor gene mutation detection. J Exp Clin Cancer Res 29:1–10
Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir R (1996) High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 56:3663–3665
Johnson NC, Dan HC, Cheng JQ (2004) Loss of XIAP in BRCA1 185delAG human ovarian surface epithelial cells results in aberrant active caspase 3 ubiquitination. Exp Cell Res 298:9–16
King MC, Marks JH, Mandell JB (2003) Breast and ovarian risks due to the inherited mutations in BRCA1 and BRCA2. Science 302:643–646
Kumar BV, Lakhotia S, Ankathil1R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K (2002) Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 1:18–23
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Nagi SA, Mazen K, Toufic E, Abdul Rahman, EK, Maya C, Fady G (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5:33–225
Narod SA (2006) Modifiers of risk of hereditary breast cancer. Oncogene 25:5832–5836
Nelson HD, Huffman LH, Fu R, Harris EL (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Prevention Services Task Force. Ann Intern Med 143:362–379
Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, El-Khatib O (2003) Breast cancer in Egypt: a review of disease presentation and detection strategies. East Mediterr Health J 9:448–463
Parvin GD, Sankaran S (2006) The BRCA1 E3 ubiquitin ligase controls centrosome dynamics. Cell Cycle 5:1946–1950
Santarosa M, Dolcetti R, Magri MD (1999) BRCA1 and BRCA2 gene: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 83:5–9
Szabo C, Masiello A, Ryan JF, Brody LC (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131. http://research.nhgri.nih.gov/projects/bic/Member/index.shtml. Accessed 25 Feb 2013
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AK, Shizuya H, Eyfjord JE, Cannon-Albright L, Tranchant M, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333–337
Tavtigian SV, Thomas A, Frank TS, Skolnick MH (1998) The BRCA1 gene and its protein product: characterization, therapeutic and diagnostic implications. Adv Oncol 14:3–13
Tavtigian SV, Samollow PB, de Silva D (2006) An analysis of unclassified missense substitutions in human BRCA1. Fam Cancer 5:77–88
Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117–119
Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337–1339
Tonin P, Weber B, Offit K, Couch F, Rebbeck T, Neuhausen S (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183
Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE (2002) The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39:457–462
Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103–105
Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866–871
Zou W (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5:263–274
Author information
Authors and Affiliations
Corresponding author
Additional information
GenBank accession nos.
These sequence variants and their controls have been submitted to GenBank: HQ221559, HQ221560, HQ221561, HQ221562, 1260166, 1259889, HQ221557, HQ221558, HQ221555, and HQ221556.
Rights and permissions
About this article
Cite this article
Bensam, M., Hafez, E., Awad, D. et al. Detection of New Point Mutations of BRCA1 and BRCA2 in Breast Cancer Patients. Biochem Genet 52, 15–28 (2014). https://doi.org/10.1007/s10528-013-9623-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-013-9623-8